Vaccine Therapy and Sargramostim in Treating Patients With Sarcoma or Brain Tumor

Completed · Phase 1

Conditions studied: Brain and Central Nervous System Tumors, Gastrointestinal Stromal Tumor, Sarcoma

In brief

RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Colony-stimulating factors such as sargramostim increase the number of immune cells found in bone marrow or peripheral blood. Combining vaccine therapy with sargramostim may cause a stronger immune response and kill more tumor cells. PURPOSE: This phase I trial is studying the side effects of vaccine therapy when given together with sargramostim in treating patients with advanced sarcoma or brain tumor.

Key facts

Study ID

NCT00069940

Run by

Dana-Farber Cancer Institute

Starts

2000-12-01

Expected to finish

2008-08-01

Last updated by the study team

2010-12-28

Who can join

Age: 2 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.